Kindred Biosciences Debt 2024

Kindred Biosciences Aktienanalyse

What does Kindred Biosciences do?

Kindred Biosciences Inc. is a biopharmaceutical company that was founded in 2012 by Richard Chin, an experienced pharmaceutical entrepreneur. The company's goal is to develop and bring to market innovative animal medicines for pets. The business model of Kindred Biosciences is based on the identification and development of novel, safe, and effective animal medicines for dogs, cats, and horses. The company utilizes state-of-the-art technologies and research methods to develop high-quality products that meet the needs of veterinarians and pet owners. The company currently has three main business segments: biologics, biopharmaceuticals, and small molecules. Each of these segments focuses on specific animal diseases and offers a unique range of products. The biologics segment of Kindred Biosciences develops innovative vaccines for dogs and cats that are highly effective and have improved tolerability. Kindred Biosciences' vaccines are specifically tailored to the needs of pets and can help prevent infections and diseases in dogs and cats. The biopharmaceuticals segment of Kindred Biosciences develops novel therapies for chronic diseases in dogs and cats, such as chronic pain, inflammation, and cancer. The company utilizes state-of-the-art technologies and research methods to develop effective and safe therapies that meet the needs of veterinarians and pet owners. The small molecules segment of Kindred Biosciences develops novel drugs for horses that are highly effective and have improved tolerability. Kindred Biosciences' drugs are specifically tailored to the needs of horses and can help treat various conditions such as arthritis or colic. The company has a broad range of products, currently consisting of over a dozen products that focus on different animal species, diseases, and needs. These include therapies for chronic pain, inhalation anesthetics, drugs for cancer and inflammation, as well as vaccines for various infections. Kindred Biosciences has achieved significant success in recent years. The company has conducted numerous clinical trials and brought several drugs and vaccines to market. In 2018, the company received approval from the Food and Drug Administration (FDA) for a groundbreaking therapy for chronic pain in dogs. The company also has a strong pipeline of products in development that could contribute to supporting the company's growth in the coming years. In summary, Kindred Biosciences is an innovative biopharmaceutical company focused on the development and commercialization of innovative animal medicines. The company has a broad range of products and is capable of developing high-quality products for a variety of animal species, diseases, and needs. With a strong pipeline and a successful track record, Kindred Biosciences is well-positioned to solidify its leading position in the industry and accelerate its growth in the coming years. Kindred Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Kindred Biosciences's Debt Structure

Kindred Biosciences's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Kindred Biosciences's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Kindred Biosciences’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Kindred Biosciences’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Kindred Biosciences Stock

What is the debt of Kindred Biosciences this year?

Kindred Biosciences has a debt level of 0 USD this year.

What was the debt of Kindred Biosciences compared to the previous year?

The debt of Kindred Biosciences has increased by 0% compared to the previous year dropped.

What are the consequences of high debt for investors in Kindred Biosciences?

High debt can pose a risk for investors of Kindred Biosciences, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Kindred Biosciences?

Low debt means that Kindred Biosciences has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Kindred Biosciences affect the company?

An increase in debt of Kindred Biosciences can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Kindred Biosciences affect the company?

A reduction in debt of Kindred Biosciences can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Kindred Biosciences?

Some factors that can influence the debt of Kindred Biosciences include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Kindred Biosciences so important for investors?

The debts of Kindred Biosciences are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Kindred Biosciences take to change the debt?

To change the debt, Kindred Biosciences can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Kindred Biosciences pay?

Over the past 12 months, Kindred Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Kindred Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Kindred Biosciences?

The current dividend yield of Kindred Biosciences is .

When does Kindred Biosciences pay dividends?

Kindred Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Kindred Biosciences?

Kindred Biosciences paid dividends every year for the past 0 years.

What is the dividend of Kindred Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kindred Biosciences located?

Kindred Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kindred Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kindred Biosciences from 6/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/3/2024.

When did Kindred Biosciences pay the last dividend?

The last dividend was paid out on 6/3/2024.

What was the dividend of Kindred Biosciences in the year 2023?

In the year 2023, Kindred Biosciences distributed 0 USD as dividends.

In which currency does Kindred Biosciences pay out the dividend?

The dividends of Kindred Biosciences are distributed in USD.